ArticleAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2015
Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.
Article in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Risk-reducing medications for primary breast cancer: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).BMC medical informatics and decision making · 2024Trial
- Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- A pilot study of a behavior-change intervention for preventive therapy among women at high risk for invasive breast cancer.BMC medical informatics and decision making · 2026Article
- Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Comparing Breast Cancer and Cardiovascular Risk among Women Undergoing Screening Mammography: Why Are Statins More Widely Accepted Compared with Chemoprevention?Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Article
- The symptom burden of women with a known risk of breast cancer receiving risk reducing medication.Cancer treatment and research communications · 2025Article
- Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women's risk-reduction experiences.BMC women's health · 2021Article
- Article
- Article
- Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal CarcinomaCancer prevention research (Philadelphia, Pa.) · 2017Article
- Decision making for breast cancer prevention among women at elevated risk.Breast cancer research : BCR · 2017Review
- Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.Oncotarget · 2017Review
- How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?NPJ breast cancer · 2017Article
- Cancer Prevention: Obstacles, Challenges and the Road Ahead.Journal of the National Cancer Institute · 2016Review
- The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients.Integrative cancer therapiesArticle
- Physician and Patient Barriers to Breast Cancer Preventive Therapy.Current breast cancer reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Breast cancer is the most common malignancy among women in the United States, and the primary prevention of this disease is a major public health issue. Because there are relatively few modifiable breast cancer risk factors, pharmacologic interventions with antiestrogens have the potential to significantly affect the primary prevention setting. Breast cancer chemoprevention with selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene, and with aromatase inhibitors (AIs) exemestane and anastrozole, is underutilized despite several randomized controlled trials demonstrating up to a 50% to 65% relative risk reduction in breast cancer incidence among women at high risk. An estimated 10 million women in the United States meet high-risk criteria for breast cancer and are potentially eligible for chemoprevention, but less than 5% of women at high risk who are offered antiestrogens for primary prevention agree to take it. Reasons for low chemoprevention uptake include lack of routine breast cancer risk assessment in primary care, inadequate time for counseling, insufficient knowledge about antiestrogens among patients and providers, and concerns about side effects. Interventions designed to increase chemoprevention uptake, such as decision aids and incorporating breast cancer risk assessment into clinical practice, have met with limited success. Clinicians can help women make informed decisions about chemoprevention by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of antiestrogens. Widespread adoption of chemoprevention will require a major paradigm shift in clinical practice for primary care providers (PCPs). However, enhancing uptake and adherence to breast cancer chemoprevention holds promise for reducing the public health burden of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.